European Biotech Acquisition Corp.
Status: Closed Deal
U=S+W/3
W=S@11.50
| IPO Proceeds, $M | $127.55M |
|---|---|
| IPO Date | Mar 16, 2021 |
| CEO | Eduardo Bravo Fernandez de Araoz |
| Left Lead | Credit Suisse |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24 months |
| IPO Sector | Healthcare ▶ |
| IPO Geography | Europe |
| Target Company | Oculis |
| Deal Announced | Oct 17, 2022 |
| Deal Size, $M | $218.00M |
| Deal Sector | Healthcare |
| Deal Geography | Global |
| SEC Filings |
www.sec.gov 
|
| Approval Vote | Feb 28, 2023 |
| Amendment Vote | TBD |
| Closing Date | Mar 2, 2023 |
Formerly EBAC
OCS
OCSAW
| Price | $17.89 |
|---|---|
| Last closing price | $17.86 |
| H/L, today | $17.35 / $17.65 |
| H/L, 52-week | $6.26 / $14.50 |
| Volume, today | 27,273 |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in to view structure, cap table, and calendar of events.